Frank Wesley Rockhold

Conference Am Heart J · June 2022 BACKGROUND: The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches trial demonstrated no overall difference in the composite primary endpoint and the secondary endpoints of cardiovascular (CV) death/myocardial infa ... Full text Link to item Cite

An Add-on Reliever-Triggered Inhaled Corticosteroid Strategy Reduces Severe Asthma Exacerbations in a Real-World Study of African American/Black and Hispanic/Latinx Patients with Asthma

Conference AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE · May 1, 2022 Link to item Cite

TOTAL CARDIOVASCULAR AND LIMB EVENTS WITH TICAGRELOR AND CLOPIDOGREL IN PATIENTS WITH SYMPTOMATIC PAD IN THE EUCLID TRIAL

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · March 8, 2022 Link to item Cite

Successfully Reducing Severe Asthma Exacerbations and Improving Asthma Control in a Pragmatic Study in African American/Black (AA/B) and Hispanic/Latinx (H/L) Patients with Moderate-Severe Asthma (PREPARE)

Conference JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY · February 2022 Link to item Cite

MYOCARDIAL INFARCTION RATES BY DEFINITION, TYPE, AND TREATMENT IN THE ISCHEMIA-CKD TRIAL

Conference Journal of the American College of Cardiology · May 2021 Full text Cite

The MARBLE Study: Modulating ApoE signaling to Reduce Brain inflammation, deLirium, and postopErative Cognitive Dysfunction

Conference ANESTHESIA AND ANALGESIA · May 2020 Link to item Cite

Risk Factor Control and Secondary Prevention of Cardiovascular Events in Peripheral Artery Disease: Insights From the Euclid Trial

Conference CIRCULATION · November 19, 2019 Link to item Cite

The Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial

Conference CIRCULATION · November 19, 2019 Link to item Cite

TCT-555 The Association of Health-Related Quality-of-Life Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID Trial

Conference Journal of the American College of Cardiology · October 2019 Full text Cite

P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.

Conference JAMA Cardiol · July 1, 2019 IMPORTANCE: Physician behavior in response to knowledge of a patient's CYP2C19 clopidogrel metabolizer status is unknown. OBJECTIVE: To investigate the association of mandatory reporting of CYP2C19 pharmacogenomic testing, provided to investigators with no ... Full text Open Access Link to item Cite

Moderate to severe renal insufficiency and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial

Conference EUROPEAN HEART JOURNAL · August 1, 2018 Link to item Cite

The occurrence of stroke and TIA in patients with peripheral artery disease and the effect of ticagrelor versus clopidogrel in EUCLID

Conference EUROPEAN HEART JOURNAL · August 1, 2017 Link to item Cite

Panel discussion of case study 3

Conference Clinical Trials · September 23, 2005 Full text Cite

Discussion: Frank W Rockhold and G Enas, data monitoring and interim analyses in the pharmaceutical industry: Ethical and logistical considerations: George W Williams et al, monitoring of clinical trials and interim analyses from a drug sponsor's point of view

Conference Statistics in Medicine · January 1, 1993 Cite